Skip to main content

Table 1 Overview of basic characteristics of heart failure and cardiovascular outcome trials published in 2021

From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Study name

Study status

Drug

Drug class

Intervention

Primary outcome

n

Median follow up

Start and end date

Clinicaltrials.gov ID

EMPEROR-preserved [37]

Completed

Empagliflozin

SGLT2 inhibitor

Empagliflozin 10 mg once daily vs. placebo

Composite of CV death or HHF

5988

2.2

03.2017–04.2021

NCT03057951

FIGARO-DKD

[36]

Completed

Finerenone

Mineralocorticoid receptor antagonist

Finerenone 10 mg or 20 mg once daily vs. placebo

Composite of death from CV causes, nonfatal MI, nonfatal stroke, or HHF

8246

3.4

09.2015–02.2021

NCT02545049

AMPLITUDE-O

[35]

Terminated

Efpeglenatide

GLP-1 receptor agonist

Efpeglenatide 4 mg or 6 mg subcutaneous once a week vs. placebo

Composite of nonfatal MI, nonfatal stroke, or death from CV or undetermined causes

4077

1.8

04.2018–12.2020

NCT03496298

  1. HHF hospitalization for heart failure